Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$16.91 -2.9%	$18.91	$16.10 ▼ $43.76	$2.13B	0.73	2.29 million shs	3.42 million shs
ARWR Arrowhead Pharmaceuticals	$16.06 -4.5%	$13.39	$9.57 ▼ $30.41	$2.22B	0.89	1.52 million shs	1.90 million shs
BCYC Bicycle Therapeutics	$8.22 -5.5%	$7.98	$6.10 ▼ $28.67	$569.27M	1.6	393,926 shs	215,209 shs
MIRM Mirum Pharmaceuticals	$44.34 +0.8%	$42.62	$23.99 ▼ $54.23	$2.20B	0.95	519,724 shs	336,375 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-2.87%	-3.04%	-11.97%	-32.76%	-58.87%
ARWR Arrowhead Pharmaceuticals	-4.52%	+6.15%	+15.62%	-15.07%	-29.78%
BCYC Bicycle Therapeutics	-5.52%	+2.11%	-3.97%	-25.07%	-62.38%
MIRM Mirum Pharmaceuticals	+0.77%	+0.77%	+2.05%	-6.79%	+83.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.5259 of 5 stars	4.3	2.0	4.4	2.9	2.5	0.6
ARWR Arrowhead Pharmaceuticals	3.6936 of 5 stars	3.3	2.0	3.4	2.8	2.5	0.0
BCYC Bicycle Therapeutics	3.2598 of 5 stars	4.4	1.0	0.0	2.0	4.2	0.6
MIRM Mirum Pharmaceuticals	3.9908 of 5 stars	3.6	0.0	4.2	3.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$39.89	135.92% Upside
ARWR Arrowhead Pharmaceuticals	2.67	Moderate Buy	$42.13	162.30% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	204.14% Upside
MIRM Mirum Pharmaceuticals	3.17	Buy	$60.73	36.96% Upside

Current Analyst Ratings Breakdown

Latest BCYC, APLS, MIRM, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$775.84M	2.74	N/A	N/A	$1.64 per share	10.31
ARWR Arrowhead Pharmaceuticals	$545.21M	4.07	N/A	N/A	$1.54 per share	10.43
BCYC Bicycle Therapeutics	$25.72M	22.13	N/A	N/A	$12.35 per share	0.67
MIRM Mirum Pharmaceuticals	$379.25M	5.79	N/A	N/A	$5.33 per share	8.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$528.63M	-$1.79	N/A	N/A	N/A	-34.97%	-103.11%	-28.96%	8/7/2025 (Estimated)
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	8/7/2025 (Estimated)
BCYC Bicycle Therapeutics	-$180.66M	-$3.14	N/A	N/A	N/A	-450.64%	-27.35%	-20.81%	8/5/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$163.41M	-$1.61	N/A	N/A	N/A	-31.69%	-41.22%	-14.81%	8/6/2025 (Estimated)

Latest BCYC, APLS, MIRM, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million
2/28/2025	Q4 2024	APLS Apellis Pharmaceuticals	-$0.37	-$0.29	+$0.08	-$0.29	$197.92 million	$212.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	1.91	4.36	3.73
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
BCYC Bicycle Therapeutics	N/A	17.13	17.13
MIRM Mirum Pharmaceuticals	1.33	3.34	3.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
ARWR Arrowhead Pharmaceuticals	62.61%
BCYC Bicycle Therapeutics	86.15%
MIRM Mirum Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
ARWR Arrowhead Pharmaceuticals	4.30%
BCYC Bicycle Therapeutics	22.90%
MIRM Mirum Pharmaceuticals	14.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	115.93 million	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.18 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.54 million	37.03 million	Optionable

BCYC, APLS, MIRM, and ARWR Headlines

Recent News About These Companies

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Position Decreased by Two Sigma Investments LP

May 29 at 3:58 AM | marketbeat.com

Man Group plc Invests $289,000 in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 29 at 3:40 AM | marketbeat.com

Mirum Pharmaceuticals’ SWOT analysis: rare disease stock shows growth potential

May 27, 2025 | investing.com

Voloridge Investment Management LLC Sells 85,242 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 27, 2025 | marketbeat.com

Two Sigma Advisers LP Trims Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 26, 2025 | marketbeat.com

Woodline Partners LP Acquires 73,399 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 24, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $29.86 Million Stock Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 24, 2025 | marketbeat.com

Equities Analysts Offer Predictions for MIRM Q2 Earnings

May 23, 2025 | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Rafferty Asset Management LLC

May 23, 2025 | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Bought by Millennium Management LLC

May 23, 2025 | marketbeat.com

Mirum Pharmaceuticals at RBC Conference: Strategic Growth Highlights

May 22, 2025 | uk.investing.com

What is HC Wainwright's Estimate for MIRM Q2 Earnings?

May 22, 2025 | americanbankingnews.com

HC Wainwright Reaffirms Buy Rating for Mirum Pharmaceuticals (NASDAQ:MIRM)

May 21, 2025 | marketbeat.com

Mirum Pharmaceuticals (NASDAQ:MIRM) Given Buy Rating at HC Wainwright

May 21, 2025 | americanbankingnews.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Tang Capital Management LLC

May 20, 2025 | marketbeat.com

Tema Etfs LLC Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 20, 2025 | marketbeat.com

Deutsche Bank AG Has $7 Million Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 20, 2025 | marketbeat.com

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 19, 2025 | businesswire.com

D. E. Shaw & Co. Inc. Purchases Shares of 157,352 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 18, 2025 | marketbeat.com

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by Prosight Management LP

May 17, 2025 | marketbeat.com

Balyasny Asset Management L.P. Purchases New Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, APLS, MIRM, and ARWR Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$16.91 -0.50 (-2.87%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$16.89 -0.02 (-0.12%)

As of 05/30/2025 05:56 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.06 -0.76 (-4.52%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$16.02 -0.04 (-0.22%)

As of 05/30/2025 05:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Bicycle Therapeutics NASDAQ:BCYC

$8.22 -0.48 (-5.52%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$8.21 -0.01 (-0.12%)

As of 05/30/2025 07:30 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Mirum Pharmaceuticals NASDAQ:MIRM

$44.34 +0.34 (+0.77%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$47.71 +3.37 (+7.60%)

As of 05/30/2025 04:44 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time